Search…

New stock news | Yifang Biotechnology (688382.SH) Hong Kong IPO prospectus invalidated

02/07/2026

According to Choicetour Financial APP, the prospectus of Yifang Biotechnology (Shanghai) Co., Ltd. (referred to as Yifang Biotechnology, 688382.SH) submitted for listing on the Hong Kong Stock Exchange on January 1, 2026 expires after 6 months, on July 1, 2026, with CITIC Securities as its exclusive sponsor.

Latest

2 m ago

Affected by concerns about the war in Iran, house prices in New Zealand are approaching a three-year low.

2 m ago

36 A-share companies pre-announce their semi-annual reports, with 29 of them expected to report positive performances.

4 m ago

In the week ending June 26, Japan bought foreign bonds worth 280.1 billion yen, revised from the previous value of 199.7 billion yen to 202.1 billion yen. Foreign investors bought Japanese stocks worth -1816.5 billion yen, revised from 479.4 billion yen to 451.3 billion yen. Japan bought foreign stocks worth 147.7 billion yen, revised from 426.8 billion yen to 426.7 billion yen. Foreign investors bought Japanese bonds worth -493.7 billion yen, previous value was -1057.3 billion yen.

5 m ago

Public offering fund outlook for the second half of the year: Investment logic is shifting from valuation-driven to performance-driven.

6 m ago

Apple (AAPL.US) is preparing a new product lineup for 2027: the iPad Pro upgrade is imminent, while the entry-level MacBook Pro may receive a completely new design.

See all latest